Frankfurt - Delayed Quote EUR

uniQure N.V. (UQ1.F)

Compare
15.23
+0.01
+(0.03%)
At close: January 10 at 9:07:20 AM GMT+1

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Matthew Craig Kapusta CPA CEO & Executive Director 992.16k -- 1972
Mr. Christian Klemt CFO, Principal Financial Officer & GM of Amsterdam Site 561.21k -- 1973
Mr. Richard Porter Ph.D. Chief Business & Scientific Officer 714.03k -- 1968
Dr. Jeannette Potts J.D., Ph.D. Chief Legal & Compliance Officer and Corporate Secretary 619.82k -- 1962
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany -- -- --
Dr. Amin Abujoub Ph.D. Chief Technical Operations -- -- --
Dr. Tamara Tugal Ph.D., MBA Business Development Director -- -- --
Ms. Erin Boyer Chief People & Culture Officer -- -- --
Dr. Walid Abi-Saab M.D. Chief Medical Officer -- -- 1965
Eileen Sawyer Vice President of Global Medical Affairs -- -- --

uniQure N.V.

Paasheuvelweg 25
Amsterdam, 1105 BP
Netherlands
31 20 240 6000 https://www.uniqure.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
480

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.’s ISS Governance QualityScore as of January 1, 2025 is 3. The pillar scores are Audit: 8; Board: 3; Shareholder Rights: 1; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 24, 2025 at 12:05 PM UTC - March 1, 2025 at 12:05 PM UTC

uniQure N.V. Earnings Date

Recent Events

Related Tickers